Width: | 250 |
Tradename: | Yupelri |
Dailymedid: | Revefenacin |
Routes Of Administration: | Inhalation |
Atc Prefix: | R03 |
Atc Suffix: | BB08 |
Legal Us: | Rx-only |
Cas Number: | 864750-70-9 |
Pubchem: | 11753673 |
Drugbank: | DB11855 |
Chemspiderid: | 9928376 |
Unii: | G2AE2VE07O |
Kegg: | D10978 |
C: | 35 |
H: | 43 |
N: | 5 |
O: | 4 |
Smiles: | CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N |
Stdinchi: | 1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43) |
Stdinchikey: | FYDWDCIFZSGNBU-UHFFFAOYSA-N |
Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018.[1] It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.[2]
Revefenacin is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist.[3]
In some countries, Yupelri is marketed by Viatris after Upjohn merged with Mylan to create Viatris.[4] [5]